RB1 mutation status and its relationship to outcomes has also been reported for breast cancer with contrasting results.28, 29 SCLC is a chemosensitive disease with initial response rates to chemotherapy for extensive stage SCLC of about 70%. This evidence concerns the gene RB1 and breast carcinoma.